Torrent Pharma Fixes July 17, 2026 as Record Date for J.B. Chemicals Amalgamation
Torrent Pharmaceuticals has set July 17, 2026, as the record date for its amalgamation with J. B. Chemicals & Pharmaceuticals. Shareholders of J.B. Chemicals will receive 51 Torrent Pharma shares for every 100 shares held, as per the sanctioned scheme.
The fixing of a record date is a crucial step in the amalgamation process, directly affecting shareholders of both companies and signaling progress towards the merger. This has a medium-term impact on corporate structure and potentially future financial performance.
The announcement is a procedural update regarding a previously decided amalgamation, fixing a record date. It does not contain new financial information or strategic shifts that would positively or negatively impact the sentiment.
Torrent Pharmaceuticals Limited has announced that Friday, July 17, 2026, has been fixed as the Record Date for determining the shareholders of J. B. Chemicals & Pharmaceuticals Limited who are eligible to receive Torrent Pharma equity shares as per the amalgamation scheme.
This decision follows the sanction of the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited by the Hon’ble National Company Law Tribunal, Ahmedabad Bench, via an order dated July 6, 2026. The scheme outlines a share exchange ratio where shareholders of J. B. Chemicals will receive 51 fully paid-up equity shares of Torrent Pharma (face value ₹5 each) for every 100 fully paid-up equity shares of J. B. Chemicals (face value ₹1 each).
The company has officially intimated this record date to both BSE Limited and the National Stock Exchange of India Ltd. on July 7, 2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under amalgamation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.